HIV-1 gp41: Role in HIV entry and prevention

被引:4
作者
Chen, YH [1 ]
Xiao, Y
Dierich, MP
机构
[1] Tsinghua Univ, Immunol Lab, Res Ctr Med Sci, Beijing 100084, Peoples R China
[2] Tsinghua Univ, Sch Life Sci & Engn, Beijing 100084, Peoples R China
[3] Univ Innsbruck, Inst Hyg, Ludwig Boltzmann Inst AIDS Res, A-6020 Innsbruck, Austria
基金
中国国家自然科学基金; 奥地利科学基金会;
关键词
D O I
10.1016/S0171-2985(00)80085-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Interaction of the envelope glycoprotein gp120 of the human immunodeficiency virus type 1 (HIV-1) with CD4 molecules (HIV-1 receptor) and then with the chemokine receptors (a co-receptor for HIV-1) on the helper T lymphocytes and macrophages initiates viral entry into the target cells (1-4), and gp120 hence has priority over other virals proteins to be used for developing a subunit vaccine against HIV-1 in many laboratories. Nevertheless, over the last few years it has emerged that HIV-1 transmembrane glycoprotein gp14 plays a special role in HIV-1 entry into the target cells and in developing an effective HIV vaccine. A putative cellular receptor for HIV-1 gp41 has been characterised by three groups (5-8). Recent crystal structure analysis of gp41 indicates that two domains (N- and C-domain) on gp41 could play an important role in mediating membrane fusion and HIV-1 entry (9, 10). Moreover, several studies had provided experimental evidence that these two domains on gp41 could induce protective activity (11-15). Understanding the role of gp41 in HIV entry and prevention may promote developing effective HIV vaccine and anti-HIV drugs.
引用
收藏
页码:308 / 316
页数:9
相关论文
共 56 条
  • [41] PASSIVELY TRANSFERRED ANTIBODIES DIRECTED AGAINST CONSERVED REGIONS OF SIV ENVELOPE PROTECT MACAQUES FROM SIV INFECTION
    LEWIS, MG
    ELKINS, WR
    MCCUTCHAN, FE
    BENVENISTE, RE
    LAI, CY
    MONTEFIORI, DC
    BURKE, DS
    EDDY, GA
    SHAFFERMAN, A
    [J]. VACCINE, 1993, 11 (13) : 1347 - 1355
  • [42] ENDOPROTEOLYTIC CLEAVAGE OF GP160 IS REQUIRED FOR THE ACTIVATION OF HUMAN IMMUNODEFICIENCY VIRUS
    MCCUNE, JM
    RABIN, LB
    FEINBERG, MB
    LIEBERMAN, M
    KOSEK, JC
    REYES, GR
    WEISSMAN, IL
    [J]. CELL, 1988, 53 (01) : 55 - 67
  • [43] HIV vaccines - Magic of the occult?
    Montefiori, DC
    Moore, JP
    [J]. SCIENCE, 1999, 283 (5400) : 336 - 337
  • [44] HIV-1 neutralizing antibodies: How full is the bottle?
    Moore, JP
    Burton, DR
    [J]. NATURE MEDICINE, 1999, 5 (02) : 142 - 144
  • [45] Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41
    Muñoz-Barroso, I
    Durell, S
    Sakaguchi, K
    Appella, E
    Blumenthal, R
    [J]. JOURNAL OF CELL BIOLOGY, 1998, 140 (02) : 315 - 323
  • [46] A CONSERVED NEUTRALIZING EPITOPE ON GP41 OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    MUSTER, T
    STEINDL, F
    PURTSCHER, M
    TRKOLA, A
    KLIMA, A
    HIMMLER, G
    RUKER, F
    KATINGER, H
    [J]. JOURNAL OF VIROLOGY, 1993, 67 (11) : 6642 - 6647
  • [47] NEURATH AR, 1995, AIDS RES HUM RETROV, V11, P189
  • [48] A BROADLY NEUTRALIZING HUMAN MONOCLONAL-ANTIBODY AGAINST GP41 OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    PURTSCHER, M
    TRKOLA, A
    GRUBER, G
    BUCHACHER, A
    PREDL, R
    STEINDL, F
    TAUER, C
    BERGER, R
    BARRETT, N
    JUNGBAUER, A
    KATINGER, H
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (12) : 1651 - 1658
  • [49] CHARACTERIZATION OF A PUTATIVE CELLULAR RECEPTOR FOR HIV-1 TRANSMEMBRANE GLYCOPROTEIN USING SYNTHETIC PEPTIDES
    QURESHI, NM
    COY, DH
    GARRY, RF
    HENDERSON, LA
    [J]. AIDS, 1990, 4 (06) : 553 - 558
  • [50] RUEGG CL, 1990, J IMMUNOL, V144, P3928